Literature DB >> 22960607

NMDA GluN2B receptors involved in the antidepressant effects of curcumin in the forced swim test.

Lin Zhang1, Tianyuan Xu, Shuang Wang, Lanqing Yu, Dexiang Liu, Renzhi Zhan, Shu Yan Yu.   

Abstract

The antidepressant-like effect of curcumin, a major active component of Curcuma longa, has been previously demonstrated in the forced swimming test. However, the mechanism of this beneficial effect on immobility scores, which is used to evaluate antidepressants, remains largely uncharacterized. The present study attempts to investigate the effects of curcumin on depressive-like behavior with a focus upon the possible contribution of N-methyl-D-aspartate (NMDA) subtype glutamate receptors in this antidepressant-like effect of curcumin. Male mice were pretreated with specific receptor antagonists to different NMDA receptor subtypes such as CPP, NVP-AAM077 and Ro25-6981 as well as to a partial NMDA receptor agonist, D-cycloserine (DCS), prior to administration of curcumin to observe the effects on depressive behavior as measured by immobility scores in the forced swim test. We found that pre-treatment of mice with CPP, a broad-spectrum competitive NMDA receptor antagonist, blocked the anti-immobility effect of curcumin, suggesting the involvement of the glutamate-NMDA receptors. While pretreatment with NVP-AAM077 (the GluN2A-preferring antagonist) did not affect the anti-immobility effect of curcumin, Ro25-6981 (the GluN2B-preferring antagonist) was found to prevent the effect of curcumin in the forced swimming test. Furthermore, pre-treatment with a sub-effective dose of DCS potentiated the anti-immobility effect of a sub-effective dose of curcumin in the forced swimming test. Taken together, these results suggest that curcumin shows antidepressant-like effects in mice and the activation of GluN2B-containing NMDARs is likely to play a predominate role in this beneficial effect. Therefore, the antidepressant-like effect of curcumin in the forced swim test may be mediated, at least in part, by the glutamatergic system.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22960607     DOI: 10.1016/j.pnpbp.2012.08.017

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  11 in total

Review 1.  Polyphenols for diabetes associated neuropathy: Pharmacological targets and clinical perspective.

Authors:  Rozita Naseri; Fatemeh Farzaei; Sajad Fakhri; Fardous F El-Senduny; Miram Altouhamy; Roodabeh Bahramsoltani; Farnaz Ebrahimi; Roja Rahimi; Mohammad Hosein Farzaei
Journal:  Daru       Date:  2019-07-27       Impact factor: 3.117

2.  NMDA receptors containing GluN2C and GluN2D subunits have opposing roles in modulating neuronal oscillations; potential mechanism for bidirectional feedback.

Authors:  Zhihao Mao; Shengxi He; Christopher Mesnard; Paul Synowicki; Yuning Zhang; Lucy Chung; Alex I Wiesman; Tony W Wilson; Daniel T Monaghan
Journal:  Brain Res       Date:  2019-11-28       Impact factor: 3.252

3.  The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus.

Authors:  J Burgdorf; X-L Zhang; C Weiss; A Gross; S R Boikess; R A Kroes; M A Khan; R M Burch; C S Rex; J F Disterhoft; P K Stanton; J R Moskal
Journal:  Neuroscience       Date:  2015-09-04       Impact factor: 3.590

4.  NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory.

Authors:  M Amin Khan; David R Houck; Amanda L Gross; Xiao-Lei Zhang; Cassia Cearley; Torsten M Madsen; Roger A Kroes; Patric K Stanton; Jeffrey Burgdorf; Joseph R Moskal
Journal:  Int J Neuropsychopharmacol       Date:  2018-03-01       Impact factor: 5.176

5.  The BDNF Val66Met polymorphism regulates glucocorticoid-induced corticohippocampal remodeling and behavioral despair.

Authors:  M Notaras; X Du; J Gogos; M van den Buuse; R A Hill
Journal:  Transl Psychiatry       Date:  2017-09-19       Impact factor: 6.222

Review 6.  Curcumin in Depression: Potential Mechanisms of Action and Current Evidence-A Narrative Review.

Authors:  Tahiana Ramaholimihaso; Fayçal Bouazzaoui; Arthur Kaladjian
Journal:  Front Psychiatry       Date:  2020-11-27       Impact factor: 4.157

Review 7.  A systematic review of studies investigating the acute effects of N-methyl-D-aspartate receptor antagonists on behavioural despair in normal animals suggests poor predictive validity.

Authors:  Martin Viktorov; Matthew P Wilkinson; Victoria C E Elston; Medi Stone; Emma S J Robinson
Journal:  Brain Neurosci Adv       Date:  2022-03-12

Review 8.  An Update on the Exploratory Use of Curcumin in Neuropsychiatric Disorders.

Authors:  Nicolás Lamanna-Rama; Diego Romero-Miguel; Manuel Desco; Maria Luisa Soto-Montenegro
Journal:  Antioxidants (Basel)       Date:  2022-02-10

Review 9.  Therapeutic Potential of Polyphenols in the Management of Diabetic Neuropathy.

Authors:  Md Tanvir Kabir; Nuzhat Tabassum; Md Sahab Uddin; Faissal Aziz; Tapan Behl; Bijo Mathew; Md Habibur Rahman; Raushanara Akter; Abdur Rauf; Lotfi Aleya
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-13       Impact factor: 2.629

10.  Novel glutamatergic drugs for the treatment of mood disorders.

Authors:  Kyle Ab Lapidus; Laili Soleimani; James W Murrough
Journal:  Neuropsychiatr Dis Treat       Date:  2013-08-07       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.